# EDGAR Filing Document

**Accession Number:** 0001744682
**File Stem:** 0001193125-26-159657
**Filing Date:** 2026-4
**Character Count:** 8982
**Document Hash:** 21b4154a930117cd516ea08cedb8f3b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-159657.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001193125-26-159657

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Cloghessy Paula
- **CENTRAL INDEX KEY:** 0001744682

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43233
- **FILM NUMBER:** 26868971

**MAIL ADDRESS:**
- **STREET 1:** C/O TRANSLATE BIO, INC.
- **STREET 2:** 29 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kailera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002096997
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 508-440-9475

**MAIL ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

## Ex-24

**Exhibit 24**

**SECTION 16 AND FORM 144<br>POWER OF ATTORNEY**

With respect to holdings of and transactions in securities issued by Kailera Therapeutics, Inc. (the "***Company***"), the undersigned hereby constitutes and appoints the individuals named on **<u>Schedule A</u>** attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule 144 (***"Form 144"***), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the "***Securities Act***"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D,Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of December, 2025.

---

| |
|:---|
| /s/ Paula Ann Cloghessy |
| Paula Ann Cloghessy |

---

------

<u>Schedule A</u>

**INDIVIDUALS APPOINTED AS ATTORNEY-IN-FACT**

**WITH FULL POWER OF SUBSTITUTION AND RESUBSTITUTION**

Scott Akamine

John Mei

Corey Manchester

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Cloghessy Paula<br><sub>(Last) (First) (Middle)</sub><br>C/O KAILERA THERAPEUTICS, INC.<br>180 THIRD AVENUE, 4TH FLOOR<br><sub>(Street)</sub><br>WALTHAM, MA 02451<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Kailera Therapeutics, Inc. [ KLRA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-04-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief People Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(1)</sup> | 2034-09-19 | Common Stock | 128388 | $5.25 | D |  |
| Stock Option (right to buy) | <sup>(2)</sup> | 2034-12-09 | Common Stock | 86150 | $5.25 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2035-02-27 | Common Stock | 95350 | $5.40 | D |  |
| Stock Option (right to buy) | <sup>(4)</sup> | 2035-11-05 | Common Stock | 230728 | $7.24 | D |  |

---

### Footnotes:

(1) The options vested and became exercisable as to 25% of the total shares on June 17, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

(2) The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

(3) The options vested and became exercisable as to 25% of the total shares on February 27, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

(4) The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ John Mei, Attorney-in-fact  
**Date:** 2026-04-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**